Security
Achieve Life Sciences, Inc. Common Shares · QUIT
QUITNASDAQCommon stockCurrentCIK 949858Updated Nov 12, 2026
Name history
ONCOGENEX PHARMACEUTICALS, INC. · through Jul 31, 2017SONUS PHARMACEUTICALS INC · through Aug 7, 2008
QUIT price & chart
Loading TradingView…
NASDAQ:QUIT on TradingView ↗About the company
AchieveRx is a late-stage pharmaceutical company with a singular focus on nicotine dependence. AchieveRx’s mission is to develop medicine for people who want to quit smoking or vaping. That medicine is cytisinicline, an investigational compound. Three ideas guide the Company: simplicity, science, and second chances, for good™. To learn more, visit www. AchieveRx.com.
In the news
Achieve Life Sciences Announced Granting of New Hire Inducement Awards ↗
Achieve Life Sciences Announces Publication in Nicotine & Tobacco Research Linking Cytisinicline's Receptor Selectivity to Low Nausea Rates and Favorable Tolerability ↗
Seeking Alpha
Achieve Life Sciences appoints Benjamin Halladay as CFO ↗
Achieve a new Buy at Stifel on potential of smoking cessation drug cytisinicline ↗
Achieve Life Sciences: Thesis Intact, Setup Remains Constructive (Rating Downgrade) ↗
SEC disclosures
ACHIEVE LIFE SCIENCES, INC. files 8-K: Material Event ↗
Recent filings
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02
144 filing
SCHEDULE 13G - filed by Logos Global Management LP regarding ACHIEVE LIFE SCIENCES, INC.
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 52,040,000Source | 47,917,000Source | 190,439,000Source | 58,935,000Source | 64,791,000Source | 33,105,000Source | 27,358,000Source | 70,029,000Source | 41,790,000Source | 38,633,000Source | 19,371,000Source | 29,971,000Source |
| Property, Plant and Equipment, NetUSD | — | — | — | — | — | — | — | — | 3,000Source | 8,000Source | 13,000Source | 4,000Source |
| GoodwillUSD | 1,034,000Source | 1,034,000Source | 1,034,000Source | 1,034,000Source | 1,034,000Source | 1,034,000Source | 1,034,000Source | 1,034,000Source | 1,034,000Source | 1,034,000Source | 1,034,000Source | 1,034,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 31,930,000Source | 9,544,000Source | 47,958,000Source | 51,874,000Source | 14,756,000Source | 28,078,000Source | 13,016,000Source | 66,398,000Source | 20,929,000Source | 12,753,000Source | 15,546,000Source | 24,771,000Source |
| Assets, CurrentUSD | 50,055,000Source | 45,529,000Source | 188,294,000Source | 56,903,000Source | 62,519,000Source | 31,061,000Source | 25,000,000Source | 67,709,000Source | 39,889,000Source | 36,467,000Source | 16,982,000Source | 27,330,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 1,941,000Source | 2,618,000Source | — | 1,506,000Source | 1,206,000Source | — | 1,755,000Source | 1,311,000Source | — | 2,107,000Source | 1,325,000Source | 2,454,000Source |
| Operating Lease, Right-of-Use AssetUSD | 79,000Source | 20,000Source | 34,000Source | 93,000Source | 35,000Source | 49,000Source | 106,000Source | 51,000Source | 64,000Source | 119,000Source | 66,000Source | 123,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 18,425,000Source | 16,539,000Source | 205,115,000Source | 17,267,000Source | 22,506,000Source | 22,427,000Source | 17,079,000Source | 20,573,000Source | 20,272,000Source | 17,734,000Source | 20,819,000Source | 21,668,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 121,000Source | 103,000Source | 170,000Source | 118,000Source | 103,000Source | 121,000Source | 103,000Source | 103,000Source | 121,000Source | 103,000Source | 90,000Source | 87,000Source |
| Retained Earnings (Accumulated Deficit)USD | -245,564,000Source | -193,218,000Source | -345,163,000Source | -231,123,000Source | -180,706,000Source | -270,394,000Source | -218,405,000Source | -172,245,000Source | -260,226,000Source | -205,578,000Source | -165,751,000Source | -135,936,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 9,000Source | 75,000Source | -88,000Source | 3,000Source | -7,000Source | 2,000Source | 6,000Source | 4,000Source | 10,000Source | 31,000Source | 4,000Source | 4,000Source |
| Stockholders' Equity Attributable to ParentUSD | 33,615,000Source | 31,378,000Source | -14,676,000Source | 41,668,000Source | 42,285,000Source | 10,678,000Source | 10,279,000Source | 49,456,000Source | 21,518,000Source | 20,899,000Source | -1,448,000Source | 8,303,000Source |
| Additional Paid in Capital, Common StockUSD | 279,049,000Source | 224,418,000Source | 330,405,000Source | 272,670,000Source | 222,895,000Source | 280,949,000Source | 228,575,000Source | 221,594,000Source | 281,613,000Source | 226,343,000Source | 164,209,000Source | 144,148,000Source |
| Liabilities and EquityUSD | 52,040,000Source | 47,917,000Source | 190,439,000Source | 58,935,000Source | 64,791,000Source | 33,105,000Source | 27,358,000Source | 70,029,000Source | 41,790,000Source | 38,633,000Source | 19,371,000Source | 29,971,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 9,730,000Source | 6,716,000Source | 197,657,000Source | 8,573,000Source | 13,702,000Source | 11,833,000Source | 7,130,000Source | 20,573,000Source | 9,082,000Source | 6,682,000Source | 20,813,000Source | 21,599,000Source |
| Operating Lease, Liability, CurrentUSD | 59,000Source | 22,000Source | 36,000Source | 58,000Source | 37,000Source | 51,000Source | 57,000Source | 53,000Source | 61,000Source | 55,000Source | 63,000Source | 58,000Source |
| Accounts Payable, CurrentUSD | 1,943,000Source | 1,011,000Source | — | 1,218,000Source | 550,000Source | — | 1,656,000Source | 373,000Source | — | 1,950,000Source | 618,000Source | 1,660,000Source |
| Operating Lease, Liability, NoncurrentUSD | 21,000Source | — | — | 37,000Source | — | — | 52,000Source | — | 5,000Source | 66,000Source | 6,000Source | 69,000Source |
| Additional Financial Items | ||||||||||||
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 48,100,000Source | 42,900,000Source | 187,300,000Source | 55,400,000Source | 61,300,000Source | 29,300,000Source | 23,200,000Source | — | 36,400,000Source | 34,400,000Source | — | — |
| Accrued Liabilities, Current | — | — | —Source | — | — | — | — | — | — | — | — | — |
| Short-term Investments | — | —Source | — | — | —Source | — | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -10,168,000Source | -12,827,000Source | -54,648,000Source | -39,827,000Source | -29,815,000Source | -42,350,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation and amortization | — | — | — | — | — | — | —Source | —Source | —Source | —Source | —Source | —Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | 2,340,000Source | 1,340,000Source | 6,955,000Source | 2,888,000Source | -685,000Source | 2,232,000Source | 8,761,000Source | 5,325,000Source | 3,439,000Source | 3,270,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -6,932,000Source | -11,088,000Source | -49,465,000Source | -29,770,000Source | -24,479,000Source | -37,549,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 14,276,000Source | 11,353,000Source | 6,111,000Source | -21,580,000Source | -21,000Source | — |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | — | 3,000Source | — | 21,000Source | — |
| Cash flows from financing activities: | ||||||||||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | — | — | — | — | — | 0Source | 114,000Source | 220,000Source | 47,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 21,000Source | — | 51,527,000Source | 48,527,000Source | 15,278,000Source | 19,295,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 7,364,000Source | 263,000Source | 8,176,000Source | -2,823,000Source | -9,225,000Source | -18,251,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Amortization of Debt Issuance CostsUSD | — | — | — | — | — | — | 12,000Source | 14,000Source | 52,000Source | 23,000Source | — | — |
| Amortization of Intangible AssetsUSD | — | — | 100,000Source | 100,000Source | — | 100,000Source | 100,000Source | 100,000Source | 200,000Source | 200,000Source | 200,000Source | 200,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 48,100,000Source | 42,900,000Source | 187,300,000Source | 55,400,000Source | 29,300,000Source | 23,200,000Source | 36,400,000Source | 34,400,000Source | — | — |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | -283,000Source | — | — | — | — | — | -283,000Source | — | — |
| General and Administrative ExpenseUSD | — | — | 9,372,000Source | 4,857,000Source | — | 5,856,000Source | — | 5,797,000Source | — | 16,252,000Source | 11,436,000Source | 10,722,000Source |
| GoodwillUSD | — | — | 1,034,000Source | 1,034,000Source | 1,034,000Source | 1,034,000Source | 1,034,000Source | 1,034,000Source | 1,034,000Source | 1,034,000Source | 1,034,000Source | 1,034,000Source |
| Impairment of Intangible Assets, Finite-livedUSD | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| InterestExpenseNonoperatingUSD | — | — | 192,000Source | 366,000Source | 277,000Source | 191,000Source | 274,000Source | 185,000Source | 819,000Source | 2,180,000Source | — | — |
| Investment Income, InterestUSD | — | — | 554,000Source | 673,000Source | 1,476,000Source | 192,000Source | 297,000Source | 322,000Source | 1,495,000Source | 2,356,000Source | 825,000Source | 199,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -14,441,000Source | -12,512,000Source | -74,769,000Source | -12,718,000Source | -10,168,000Source | -12,827,000Source | -54,648,000Source | -39,827,000Source | -29,815,000Source | -42,350,000Source |
| Nonoperating Income (Expense)USD | — | — | 251,000Source | -46,000Source | -56,377,000Source | -155,000Source | 295,000Source | 67,000Source | 232,000Source | -758,000Source | -2,565,000Source | -1,550,000Source |
| Operating Lease, ExpenseUSD | — | — | 25,000Source | 29,000Source | 29,000Source | 30,000Source | 32,000Source | 31,000Source | 100,000Source | 100,000Source | 100,000Source | 100,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -5,000Source | -8,000Source | -5,000Source | -59,000Source | -13,000Source | 21,000Source | -36,000Source | -30,000Source | -9,000Source | 40,000Source |
| Payments of Financing CostsUSD | — | — | — | — | — | — | — | — | — | — | — | 20,000Source |
| Payments to Acquire InvestmentsUSD | — | — | — | — | — | — | — | — | 24,755,000Source | 47,887,000Source | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Other Nonoperating Income (Expense)USD | — | — | -5,000Source | -8,000Source | -5,000Source | -59,000Source | -13,000Source | 21,000Source | -36,000Source | -30,000Source | -9,000Source | 40,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | -54,648,000Source | -39,827,000Source | -29,815,000Source | -42,350,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -14,441,000Source | -12,512,000Source | -74,769,000Source | -12,718,000Source | -10,168,000Source | -12,827,000Source | -54,648,000Source | -39,827,000Source | -29,815,000Source | -42,350,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.28Source | -0.36Source | -0.8Source | -0.37Source | -0.19Source | -0.37Source | -1.25Source | -1.24Source | -1.5Source | -4Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.28Source | -0.36Source | -0.8Source | -0.37Source | -0.19Source | -0.37Source | -1.25Source | -1.24Source | -1.5Source | -4Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 51,017,662Source | 34,355,050Source | 93,510,544Source | 34,685,072Source | 53,381,989Source | 34,685,072Source | 43,594,652Source | 32,071,146Source | 19,827,354Source | 10,593,034Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 51,017,662Source | 34,355,050Source | 93,510,544Source | 34,685,072Source | 53,381,989Source | 34,685,072Source | 43,594,652Source | 32,071,146Source | 19,827,354Source | 10,593,034Source |
| Interest Expense (non-operating)USD | — | — | 192,000Source | 366,000Source | 277,000Source | 191,000Source | 274,000Source | 185,000Source | 819,000Source | 2,180,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | 100,000Source | 100,000Source | — | 100,000Source | 100,000Source | 100,000Source | 200,000Source | 200,000Source | 200,000Source | 200,000Source |
| Costs and ExpensesUSD | — | — | 14,692,000Source | 12,466,000Source | 18,392,000Source | 12,563,000Source | 10,463,000Source | 12,894,000Source | 54,880,000Source | 39,069,000Source | 27,250,000Source | 40,800,000Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | — | — | — | 57,000Source | 62,000Source | 228,000Source | 229,000Source | 228,000Source | 236,000Source |
| General and Administrative ExpenseUSD | — | — | 9,372,000Source | 4,857,000Source | — | 5,856,000Source | — | 5,797,000Source | — | 16,252,000Source | 11,436,000Source | 10,722,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -54,192,000Source | -39,532,000Source | -28,982,000Source | -41,660,000Source |
| Interest ExpenseUSD | — | — | — | 366,000Source | — | — | — | — | — | — | 2,853,000Source | 1,789,000Source |
| Investment Income, InterestUSD | — | — | 554,000Source | 673,000Source | 1,476,000Source | 192,000Source | 297,000Source | 322,000Source | 1,495,000Source | 2,356,000Source | 825,000Source | 199,000Source |
| Nonoperating Income (Expense)USD | — | — | 251,000Source | -46,000Source | -56,377,000Source | -155,000Source | 295,000Source | 67,000Source | 232,000Source | -758,000Source | -2,565,000Source | -1,550,000Source |
| Operating Lease, ExpenseUSD | — | — | 25,000Source | 29,000Source | 29,000Source | 30,000Source | 32,000Source | 31,000Source | 100,000Source | 100,000Source | 100,000Source | 100,000Source |
| Research and Development ExpenseUSD | — | — | 5,320,000Source | 7,609,000Source | — | 6,707,000Source | — | 7,097,000Source | — | 22,817,000Source | 15,814,000Source | 30,078,000Source |
Offerings
Registration 333-295798
Registration 333-292918
Filing attachments
achv-ex99_1.htm · 8-K · 2026-11-10
Exhibit 99.1 AchieveRx Reports Third Quarter 2026 Financial Results and Provides Business Updates Launched new corporate brand as AchieveRx, The Quit Company (Nasdaq: QUIT) Presented 52-week ORCA-OL data at the CHEST 2026 Annual Meeting showing that nearly one in three adults still smoking or vaping after a supervised quit attempt in a prior trial (a median of five quit attempts among those who smoked) had quit by the end of treatment, with quit rates rising over the course of the year Expan…
Read attachment ↗ex99_1.htm · SCHEDULE 13G · 2026-08-17
EXHIBIT 99.1 AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G The undersigned agree to file jointly with the Securities and Exchange Commission (the “SEC”) any and all statements on Schedule 13D, Schedule 13G or forms 3, 4 or 5 (and any amendments or supplements thereto) required under section 13(d) or 16(a) of the Securities Exchange Act of 1934, as amended, in connection with purchases by the undersigned of the securities of any issuer. For that purpose, the undersigned …
Read attachment ↗achv-ex99_1.htm · 8-K · 2026-08-11
EX-99.1 2 achv-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Achieve Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Updates Closed a private placement of up to $354 million, with $180 million upfront and up to $174 million from warrants exercisable prior to and up to 20 trading days following FDA approval Strengthened organization with new Chief Executive Officer, experienced commercial, CMC, and quality leaders, along with six new appointments to the Board o…
Read attachment ↗ea029733101ex99-1.htm · SCHEDULE 13G · 2026-07-08
Exhibit 99.1 Joint Filing Agreement The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of th…
Read attachment ↗achv-ex99_1.htm · S-8 · 2026-05-12
EXHIBIT 99.1 ACHIEVE LIFE SCIENCES, INC. 2024 EQUITY INDUCEMENT PLAN (Amended May 11, 2026) 1. PURPOSE. The purpose of this Plan is to provide incentives to attract and motivate eligible employees whose potential contributions are important to the success of the Company, and any Parents and Subsidiaries that exist now or in the future, by offering them an opportunity to participate in the Company’s future performance through the grant of Awards. Capitalized terms not defined elsewhere in the…
Read attachment ↗d854692dex991.htm · 8-K · 2026-05-12
EX-99.1 2 d854692dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Achieve Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Updates Closed Private Placement of Up to $354 Million, Including $180 Million Upfront and $174 Million in Milestone-Driven Warrants Appoints New CEO and Expands Board of Directors Advances U.S.-based Manufacturing Transition & Partnership Conference Call Scheduled for 8:30 AM EDT Today, May 12, 2026 SEATTLE and VANCOUVER, British Columbia, …
Read attachment ↗